Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Goodbody Health Ltd GDBYF

Goodbody Health Ltd is a wellness company operating in both COVID testing in the United Kingdom and as a vertically integrated cannabinoid CBD company that operates in the United Kingdom and the European Union. It has interests in COVID testing clinics, CBD extraction, wholesale bulk isolate, and distillate sales, retail CBD and white label sales, cannabinoid laboratory testing, and medicinal... see more

GREY:GDBYF - Post Discussion

Goodbody Health Ltd > I think people are overreacting. Everyone that owns Stil
View:
Post by Juzzmyop1nion on Feb 27, 2020 3:40pm

I think people are overreacting. Everyone that owns Stil

needs to take a look at what Opportunity C.MOTA is offering before they make a decision to be upset or not.   First off MOTA is meeting with a lot of major worldwide players who they see have their stuff together to join their team as an equal.  They are merging with STIL.  Not firing their board and taking over.  Giving an SP based on what STIL is worth so it’s fair.   They keep their entire sector moving as part of a seed to sale picture.    I spent some time checking out who MOTA has merged with and these guys aren’t playing around.   They are looking to absolutely dominate the CBD market now... not in 2 more years but now!!   China is weak and with the virus issue now is the time to make alliances and merge for the better of all.  Take a look MOTA and lmk what you guys think
Comment by yonglu1863 on Feb 27, 2020 4:58pm
It is not overreacting. Everybody want to dominating the markets. But what you will you do for it. Like Stillcanna, they said they had agreements with bioscience, sequoya, hemp labs, dragonfly bioscience. but did they really exist, or  operate or reliable? No absolute not. Why they told us these agreements, they just want to pump and dump. Now they want to do it through the merger. They did ...more  
Comment by Juzzmyop1nion on Feb 27, 2020 5:38pm
Stil can’t dominate nay market by themselves.   They would have to be a lot further ahead than where they are now.   To think everything they “claim” is false is laughable if you invest in a company that you don’t believe in is telling the truth.   STIL merging with someone that already has several other aspects of the business already ironed out just speeds up the process to ...more  
Comment by drmaddogs2 on Feb 28, 2020 9:20am
yonglu1863 You probably are aware of factors in this market but I will outline some relevant. Bioscience and Dragonfly, 'Anchor' agreements, both were started when regulatory situations hadn't stepped in or were interring flux. No one in the Industry in 2018 expected 'Novel Foods' or its full implications as the E.U. Commission rolled out the definitions in 2019. Everyone ...more  
Comment by lscfa on Feb 28, 2020 10:30am
No kidding.     MOTA trading at $0.28 x 0.555 exchange ratio => $0.155 for STIL.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities